Friday, 13 December 2013: 11:15 - 11:35
Great Lakes Grand Ballroom East (Westin - Michigan Avenue)
Learning Objectives:
Interpret the progress in developing oral immunotherapy (OIT) for food allergy, including a novel approach utilizing anti-IgE monoclonal antibody (omalizumab) in combination with OIT, especially in terms of safety and efficacy.
Interpret the progress in developing oral immunotherapy (OIT) for food allergy, including a novel approach utilizing anti-IgE monoclonal antibody (omalizumab) in combination with OIT, especially in terms of safety and efficacy.